Objective-To determine the pathological and biological characteristics of breast cancers diagnosed by screening and examined at the Edinburgh University pathology department. Methods-These cancers were classified by screening status: never screened (n=I11), prevalence screen detected (n=105), and previously screened (n=74). The last category arose in women who had been regularly screened during the trial; the cancers were diagnosed as interval cases before the first invitation to service screening (n=33) or were incidence screen detected at that time (n=41). Results-Association (for operable invasive cancers, n=250) of cancer characteristics with screening status reflects influences of biology (aggressiveness) or chronology (time of diagnosis), or both. The prognostic indicators tumour grade, histological type, and oestrogen receptor status were found in a smaller percentage of the patients with poor prognosis among the prevalence screen detected cases (9%, 77%, 18%) than among those previously screened (29%, 84%, 35%). The chronological factors size and node status were found in a smaller percentage of patients with poor prognosis among women previously screened (31%, 24%) than among those never screened (62%, 39%». Apart from these two, no other factors improved the diagnosis in the previously screened group compared with the never screened group. Conclusions-These results suggest that favourable characteristics of screen detected cases are often due to the effects of length bias on "biological factors" and fail to show that current local screening practice has succeeded in advancing the diagnosis of breast cancers to a less aggressive phase.
Abstract
Objective-To determine the pathological and biological characteristics of breast cancers diagnosed by screening and examined at the Edinburgh University pathology department. Methods-These cancers were classified by screening status: never screened (n=I11), prevalence screen detected (n=105), and previously screened (n=74). The last category arose in women who had been regularly screened during the trial; the cancers were diagnosed as interval cases before the first invitation to service screening (n=33) or were incidence screen detected at that time (n=41). Results-Association (for operable invasive cancers, n=250) of cancer characteristics with screening status reflects influences of biology (aggressiveness) or chronology (time of diagnosis), or both. The prognostic indicators tumour grade, histological type, and oestrogen receptor status were found in a smaller percentage of the patients with poor prognosis among the prevalence screen detected cases (9%, 77%, 18%) than among those previously screened (29%, 84%, 35%). The chronological factors size and node status were found in a smaller percentage of patients with poor prognosis among women previously screened (31%, 24%) than among those never screened (62%, 39%». Apart from these two, no other factors improved the diagnosis in the previously screened group compared with the never screened group. Conclusions-These results suggest that favourable characteristics of screen detected cases are often due to the effects of length bias on "biological factors" and fail to show that current local screening practice has succeeded in advancing the diagnosis of breast cancers to a less aggressive phase. The introduction of breast screening by the NHS for women aged 50-64 has allowed evaluation of the influence of screening on cancer characteristics in Edinburgh. Because of a previous randomised trial of screening in that locality' a cross sectional study between 1988 and 1991 provides a unique opportunity to examine cancers in unscreened, newly screened, and regularly screened women. Pathological and biological features are compared in three groups of cancers in members of the Edinburgh Randomised Trial (ERT) Study Group defined according to screening history: group A: prevalence (that is, first) screen detected cases, group B: cases in previously screened women, group C: cases in never screened women.
Group A represents cases arising in a population at the start of a screening programme, when screen detection rates are high and cases will have a longer mean "sojourn time" in the preclinical phase (that is, are subject to "length bias'" ).
Group B corresponds to the steady state that can be expected in a group of regularly screened women. All women in this group had had at least two negative mammographic screens (at intervals of two years) and most had had four negative screens. It includes cases detected at subsequent screening, but these are less subject to length bias than group A. If a cohort of screen negative women were followed up through their next screen the total series of cancers arising would represent early cases but should be unbiased (that is, free oflength bias'); group B approximates to this.
Group C represents disease in an unscreened population.
Comparisons of group B with C will be sensitive to the earliness of detection and identify "chronological factors" 4 that change during the life history of the tumour. On the other hand, comparisons between group A and B will indicate characteristics associated with length bias. Such factors are directly related to length of the sojourn time in the detectable preclinical phase but potentially also with growth rate and other factors related to the intrinsic turnour biology.' 4 These translate in clinical practice into variations between indolence and aggression. We shall refer to them as "biological factors".
The concepts of biological and chronological factors are not mutually exclusive. Intrinsic tumour biology may change with time (for example, a drift towards increased aggression), and this will be evident when characteristics are related to both biology and chronology. The concepts are due to Mittra and MacRae who undertook a meta-analysis' and separated 10 factors conventionally regarded as prognostic indicators into two groups. Two clinical or *The previously screened group (group B) were cancers diagnosed in women who had been screened negative within the past three years. All of these women had had at least two negative screens before their diagnosis.
anatomical factors (node status and cancer size) were correlated with each other and designated as chronological; the remaining eight factors (histological grade, oestrogen and progesterone receptor status, thymidine labelling index, DNA ploidy, S-phase fraction, epidermal growth factor expression, and c-erb-B2 gene amplification or overexpression) were also strongly correlated with each other. With the exception of histological grade no significant correlations were found between these biological factors and the chronological factors. Although this classification of cancer characteristics is controversial' and considered oversimplistic," 7 there is broad support for its use. In our study we have included the standard histopathological characteristics of size, nodal status, histological type, and combined grade as well as molecular characterisation of c-erb-B2 gene disregulation" and biochemical classification of oestrogen receptor status' These factors constitute an acceptable representation of cancer features at diagnosis. They are not, in general, available for either advanced or in situ cancer; most of the study is, therefore, restricted to operable, invasive cases.
The first objective of this study is to compare the distributions of the cancer characteristics in the three groups defined by screening status. This will indicate whether such features are chronologically or biologically determined, or both, within the standards set by current screening practice in Edinburgh. A factor whose status is improved, on average, by early detection through screening will emerge as chronological, whereas one whose distribution is more favourable in cases detected at the prevalence screen will be a biological factor. For an indicator of intrinsic aggression, where drift to a more aggressive form occurs during 153 the lead time effected by screening, associations with both chronology and biology will be evident. A second objective is to interpret these comparisons as early indicators of effectiveness of the screening programme in Edinburgh at that time.
Methods
The Edinburgh randomised trial (ERT) I was a randomised trial of breast cancer screening which recruited the majority of Edinburgh women aged 45-64 during the period 1978-85. Half these women were invited to screening and the remainder (the controls) had routine health care. The trial fieldwork continued through 1988 and included biennial mammography (four screens for entrants 1978-81, three screens for entrants 1982-3, and two screens for later entrants). When UK service screening (Forrest screening) began in Edinburgh in 1988, a substantial minority of the population had been screened regularly; these women were invited to their first Forrest screen three years after their last trial screen. Most of the remaining women in the city (in the eligible age range of 50-64) had not been screened before.
The cases for analysis were assembled in two phases. Initially, a consecutive series of breast cancers diagnosed from biopsy specimens submitted to the Edinburgh University pathology department (1989-90) in women aged 50-64 were considered for inclusion. The records for each women were matched against the database of the ERT. I Women were eligible if they could be classified into one of three screening status groups: prevalence screen detected (A), previously screened within the ERT within the past three years (B), never screened (C). Secondly, to maximise the numbers in group B, the ERT database was searched to identify women in the relevant age range «65 years when due to be invited to Forrest screening) who had attended the last trial screen and had breast cancer diagnosed subsequently, either before the first Forrest screen or at that screen. Additional women in this group were included in group B if pathological data or samples could be retrieved. Women in group B were subdivided into those whose cancers were detected at the Forrest screen (incidence screen detected-Bl) and interval cases (B2). Alexander, Anderson, Hubbard OR> 1 if A is better than B (that is, iffactor is biological).
:j: NST = no special type; ST = special type.
All women in group B I had had two to four negative mammographic screens during the ERT.
LABORATORY METHODS
Histopathological characteristics of the study set were derived from overall evaluation of material used for routine diagnosis and that processed for biological tests, as previously described.· 10 Histological type, as special or not, and grade were judged according to standard criteria." 11 Overexpression of c-erb-B2 was evaluated by immunohistochemistry with rabbit polyclonal antibody 21N 12 by a three stage peroxidase-antiperoxidase technique. 13 Amplification of c-erb-B2 was assessed by the differential polymerase chain reaction as previously published.B
STATISTICAL METHODS
The first analyses (reported in tables 2-4) compare characteristics of cancers in pairs of screening status groups determined by: Chronology dichotomy: early=previously screened cases (B) later=never screened cases (C) One screening status group is excluded from each comparison to ensure that, as far as possible, each is uninfluenced by the other criterion.
Logistic regression" has been applied (with adjustment for age in three five-year groups). Comparisons (reported in table 4) are expressed as odds ratios" ; an odds ratio less than 1 for the chronology dichotomy indicates that the baseline value (for example, small size, special type) is associated with early diagnosis (that is, group B). Similarly, an odds ratio greater than 1 for the biology dichotomy indicates that the baseline (for example, small size, special type) occurs more often in cancers whose sojourn time is lengthy (that is, group A). Multivariate analyses were used to investigate independent contributions of individual characteristics.
The second analyses (table 4) investigated the effect of biology by considering more than two groups across which a trend would be predicted, as follows: B2 (interval cases) negative length bias C (never screened) unbiased BI (incidence screen) somewhat length biased A (prevalence screen) most length biased Numbers available for analyses in some subgroups are now very small and exact methods have been applied to estimate odds ratios, compute 95% confidence intervals, and test for trend." An odds ratio > 1 corresponds to a higher proportion of cancers being at the level noted (for example, grade=3) in the group examined than in the reference group (prevalence screen detected); an increasing trend of odds ratios across the screening status groups indicates increasing proportions of cancers with, for example, grade=3, which would reflect status of grade as a biological factor.
The package EGRET was used for all statistical modelling. 16 Results Table 1 shows the numbers of cases in the three screening status groups. The consecutive series submitted to the Edinburgh University pathology department (1989-90) comprised 254 cases, of whom six were ineligible as they had been screened during the ERT and subsequently failed to attend so that their last screen was more than three years before diagnosis. This series provided all the cases in groups A and C and contributed 32 cases to group B. Altogether, 83 cancers were detected in the three year follow up of the cohort of women screened negative at the last ERT screen. Of these, 74 (89%) are included in the present analysis; of the remainder, six (one screen detected and five interval cases) had advanced disease and three interval cases could not be traced. Table 2 gives counts and percentages of invasive cancers in each screening status group which have "unfavourable" levels of each characteristic. Differences between the three groups are significant (P<0.05) for size, grade, and type, and of borderline significance (0.05<P<0.1) for node status and oestrogen receptor status. Distributions of c-erb-B2 amplification and overexpression are similar for the three groups.
Formal statistical analyses of screening status dichotomies, according to chronology (early/late) or biology (unbiased/length biased) (table 3) indicate that the difference by size (>2 cm/~2 em) is statistically highly significant for chronology and that for node status is of borderline significance. When size is considered in more detail (~1 ern, 1-2 cm, >2 em) further strong and statistically significant differences emerge but these, again, are restricted to chronology. Consideration of the four screening status groups (table 4) indicates, formally, significant or nearly significant trends for both size and node status, but inspection of the results indicates that these are attributable to differences between prevalence screen detected and never screened cases rather than to any genuine trend.
Histological grade has a strong and highly significant association with biology, whereas histological type and oestrogen receptor status 155 show less strong associations (table 3) . The trend analyses (table 4) confirm associations of both histological type and oestrogen receptor status with biology. Histological grade and oestrogen receptor status show no evidence of association with chronology. Both have high frequencies of the unfavourable characteristics for one of the categories in the previously screened group (interval cases for oestrogen receptor status and incidence screen detected for grade) and, overall, slightly "worse" distributions in the previously screened than the never screened group. The results in table 3 do, however, provide some evidence that histological type may be influenced by chronology.
The associations of size with chronology and grade with biology persist after allowing for other relevant factors in multivariate analyses.
The formal analyses confirm the indications from table 2 that neither c-erb-B2 amplification nor overexpression shows any simple association with either chronology or biology. This holds despite a strong association between oestrogen receptor (ER) status (itself associated with biology) and c-erb-B2 gene disregulation: 29% of ER and 5% of ER+ tumours had c-erb-B2 overexpressed, 60% of ER and 48% ofER+ tumours had c-erb-B2 amplified. There are, in addition, clear associations between c-erb-B2 gene disregulation and histological type (and grade), but the direction of the associations differs for overexpression and amplification-that is, 2% of ST tumours but 12% of NST tumours had c-erb-B2 overexpressed; 66% ofST tumours and 50% ofNST tumours had c-erb-B2 amplified. These results indicate the complexity of the relation between c-erb-B2 amplification and overexpression with oestrogen receptor status and with other cancer characteristics.
Discussion
Classification of characteristics of breast cancers as biological or chronological factors is simplistic. The two are difficult to define precisely, although Mittra and MacRae' formally defined chronological factors as those which were not associated with duration of survival after the first recurrence; by implication all other characteristics were biological. The biological activity of each cancer is complex and it may be appropriate to consider more than two groups of characteristics.7 Long term follow up of over 3000 cases has shown that interactions between factors are also relevant,' confirming the clinical understanding that, for example, node involvement is most indicative of aggression if the cancer is small." Critically, the realisation that cancer progresses through a succession of genetic changes questions the existence of any intrinsic biological properties of an individual cancer; all these may change with time as indolent cancers change to aggressive ones. We believe that the concepts do, nevertheless, represent a useful model for describing the average properties of groups of cancers and for investigating the consequences of screening. The definitions which we have used are clear in context but do not correspond exactly with those (often implicit) of other authors.
The cases included in the present analyses are restricted to those submitted for histological evaluation and most analyses exclude in situ cases; the ERT has shown a clear reduction in advanced disease (VICC clinical stage III and IV) in women offered screening and an increase in incidence of non-invasive cancer. " The present results compare the distributions of characteristics of invasive operable cancers in three groups determined by screening status. The two largest groups (A-prevalence screen detected cases and C-symptomatic cases in unscreened women) are consecutive series and should be representative of the relevant women in the ERT. For the unbiased group of cases in previously screened women we have included as many cases as possible from the relevant trial cohort. We have no reason to suppose that the operable cases for which pathological data could not be obtained differed from the series included in the analysis. As some interval cases were untraced, however, group B may retain a small amount of length bias. If this were true it would increase the frequency of favourable characteristics for biological factors in group B compared with group C. There is no evidence of this. The characteristics of size and node status outlined in table 2 are in keeping with previous experience of screened and unscreened subjects," 20 though the proportion of grade 3 cancers is low in all groups, particularly those never screened, where it is approximately half that reported from the two counties study," A major factor contributing to this difference is the use in that study of unmodified Bloom and Richardson grading criteria, which favour high mitotic scores with a tendency to increase the grade. Other possible factors contributing to the difference are the criteria used to determine "operability" (and thus availability of histological material) in the two studies. The between-group comparisons reported here are not subject to observer bias.
Pathological size and node status emerged as unequivocal chronological factors as we predicted in advance and as has been reported in other studies." 10 20 Histological grade, histological type, and oestrogen receptor status were clearly biological factors. This has been reported previously for grade," type," and oestrogen receptor status." Our data provide no evidence that histological grade or oestrogen receptor status are also chronological factors-that is, that screening has advanced the diagnosis to a time when either of these is more favourable. The situation is somewhat equivocal for histological type, but no clear evidence emerges that it has been modified by advancing the time of diagnosis. It is somewhat surprising that neither c-erb-B2 overexpression nor amplification emerges asa biological factor as both have been reported as prognostic indicators." The present data illustrate the complexity of the relations of gene disregulation with other prognostic indicators, cancer natural history, and cancer biology, which cannot be resolved without larger numbers. Alexander, Anderson, Hubbard The underlying rationale for breast cancer screening is that the advance of diagnosis will lead to a beneficial change in the population distribution of cancer characteristics and consequently delay or prevent deaths from breast cancer that would otherwise have occurred. The evaluation of the characteristics in a group that is undergoing regular screening can thus be an early quality control indicatorpredicting whether screening can be expected to lead to the intended reductions in breast cancer mortality.' 2. 25 Comparison of the distributions of cancer characteristics must be made when the steady state has been reached and the transient influence of the prevalence screen on the apparent distribution of the characteristics in the screened population has passed. Initial comparisons will be highly influenced by length bias as has been observed in Edinburgh and elsewhere when prevalence screen detected cases are compared with unscreened cases,":" and this can lead to unrealistic conclusions." The steady state is not generally accessible in the United Kingdom at the present time but can be estimated from the present snapshot comparing the Edinburgh mixture of women newly screened or never screened with those who had been undergoing regular screening for many years.
The association of the two types of cancer characteristic with effective screening programmes is, however, controversial. Factors which are purely chronological indicate lead time gained by earlier diagnosis. They can undoubtedly be useful early indicators of the ability of screening to advance the diagnosis and are recommended as intermediate end points in evaluation of screening," 25 but it is unclear whether they will suffice on their own. Some authors have argued' 21 that only nonbiological factors can appropriately be used in this context and that improved distribution of size and node status in previously screened compared with unscreened women is sufficient evidence that "the mortality reduction found in randomised trials can be repeated"." These authors noted that DNA flow cytometry results for cancers in previously screened women were almost identical with those in unscreened women and concluded that "biological aggressiveness... does not increase during the detectable preclinical phase (sojourn time) of breast cancer development". On the other hand, investigators from the Swedish two county trial," in which a breast cancer mortality reduction of 35% was observed (in women aged 50-64), have reported that advancing the time of diagnosis improved the grade distribution and concluded that "breast cancer is a progressive disease whose development can be arrested by early diagnosis and treatment". Modification of the grade distribution was an independent predictor of mortality benefit in addition to size and node status.
If modification of purely chronological factors and reduction in the rate of locally advanced and metastatic disease is sufficient then screening in Edinburgh around 1990 was performing well. However, in Edinburgh at that time the biological factors and, in particu-.lar, grade were not influenced by early detection; this is similar to the experience in Finland." Comparisons of cancers in the ERT control arm with an unbiased group of early cases diagnosed while the trial was in progress disclosed an improvement in histological type, though this was not statistically significant." However, the change from a two year interval between screens during the trial to a three year one for service screening reduces the ability of screening to advance diagnoses because the interval cancer rate, in particular, is substantially increased.":"
We do not share the confidence of Hakama et ai" that reduction in size and nodal involvement will ensure that screening is effective in preventing breast cancer mortality. Others" 31 have expressed concern that the UK service screening programme with a three year interval between screens may not produce the anticipated benefit, and the limited information on pathological size, node status,'2 33 and other characteristics impairs early evaluation.'4 The present results emphasise the need to record such information on all cancers in the groups offered screening but also suggest that current UK screening practice and policy may not advance the diagnosis sufficiently to alter the distributions of the biological factors.
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